LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026

SALT LAKE CITY, UT – LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, recently reported financial results for its fourth fiscal quarter ended June 30, 2026.

Fourth Quarter Fiscal 2026 Summary*:

• Revenue was $42.4 million, a decrease of 23.1% from the prior year period;
• Revenue in the Americas decreased 24.8%, and revenue in Asia/Pacific & Europe decreased 16.9%;
• Net income per diluted share was $0.10, versus $0.15 per diluted share a year ago;
• Adjusted earnings per diluted share was $0.11, compared to $0.17 a year ago; and
• Adjusted EBITDA was $2.7 million compared to $4.8 million a year ago.

^{* All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2026 to the fourth quarter of fiscal 2025, unless otherwise noted.}

Fiscal Year 2026 Summary*:

• Revenue was $182.6 million, a decrease of 20.1% from the prior year period;
• Revenue in the Americas decreased 23.2%, and revenue in Asia/Pacific & Europe decreased 6.9%;
• Net income per diluted share was $0.40, versus $0.75 per diluted share a year ago;
• Adjusted earnings per diluted share was $0.56, compared to $0.82 a year ago; and
• Adjusted EBITDA was $13.7 million compared to $22.1 million a year ago.

^{* All comparisons are fiscal year 2026 to fiscal year 2025.}

“It’s a privilege to lead LifeVantage at this stage of its journey and my conviction about this Company is stronger today than when I accepted the role,”

said Terrence Moorehead, President and Chief Executive Officer.

“With a differentiated, science-backed platform, strong gross margins and a debt-free balance sheet, our foundation is strong and I believe we have a real competitive advantage. Our early focus will be on strengthening the LifeVantage brand, building a more relevant consumer proposition, and driving operational excellence. Despite the challenges reflected in our recent results, I’m optimistic about what lies ahead. We intend to move forward with a real sense of urgency and look forward to sharing more about our strategy as our work progresses.”

Fourth Quarter Fiscal 2026 Results

For the fourth quarter ended June 30, 2026, the Company reported revenue of $42.4 million, a 23.1% decrease compared to revenue of $55.1 million in the fourth quarter of fiscal 2025. Revenue in the Americas region decreased 24.8% and revenue in the Asia/Pacific & Europe region decreased 16.9%. These decreases were primarily due to due to downward pressure in the number of orders from our active account base and lower average order size, reflecting impacts from the broader macro-economic environment, as well lower sales of our MindBody GLP-1 System cycling the higher comparable fourth quarter of fiscal 2025, partially offset by sales of LoveBiome, which we acquired in October 2025.

Gross profit for the fourth quarter of fiscal 2026 was $33.0 million, or 78.0% of revenue, compared to $44.0 million, or 79.9% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to a shift in product mix, inventory obsolescence expenses, and increases in shipping related expenses.

Commissions and incentives expense for the fourth quarter of fiscal 2026 was $17.5 million, or 41.3% of revenue, compared to $23.2 million, or 42.1% of revenue, for the same period in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year period is primarily due to the timing and magnitude of promotional and incentive programs and changes to the sales mix between customers and independent consultants.

Selling, general and administrative (SG&A) expense for the fourth quarter of fiscal 2026 was $13.9 million, or 32.7% of revenue, compared to $18.7 million, or 33.9% of revenue, for the same period in fiscal 2025. The decrease in SG&A expenses as a percentage of revenue was primarily due to decreases in variable employee compensation expenses and lower event related expenses.

Operating income for the fourth quarter of fiscal 2026 was $1.7 million compared to $2.1 million for the same period in fiscal 2025. Adjusted non-GAAP operating income for the fourth quarter of fiscal 2026 was $1.8 million compared to adjusted non-GAAP operating income of $2.5 million for the same period in fiscal 2025.

Net income for the fourth quarter of fiscal 2026 was $1.3 million, or $0.10 per diluted share, compared to $2.0 million, or $0.15 per diluted share for the same period in fiscal 2025. Adjusted non-GAAP net income for the fourth quarter of fiscal 2026 was $1.4 million, or $0.11 per diluted share, compared to adjusted non-GAAP income of $2.3 million, or $0.17 per diluted share, in the same period of fiscal 2025.

Adjusted EBITDA was $2.7 million for the fourth quarter of fiscal 2026, versus $4.8 million for the comparable period in fiscal 2025.

Full Year Fiscal 2026 Results

For the fiscal year ended June 30, 2026, the Company reported revenue of $182.6 million, a 20.1% decrease compared to revenue of $228.5 million in fiscal 2025. Revenue in the Americas region decreased 23.2% and revenue in the Asia/Pacific & Europe region decreased 6.9%. These decreases were primarily due to declines in sales of the MindBody GLP-1 System^®, declines in the number of orders from our active account base, and average order size. These declines were partially offset by sales of LoveBiome, which the Company acquired in October 2025.

Gross profit for fiscal 2026 was $141.6 million, or 77.6% of revenue, compared to $183.7 million, or 80.4% of revenue in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System^®, along with a shift in product mix. Adjusted for the allowance for inventory obsolescence, non-GAAP gross profit for fiscal 2026 was $144.1 million, or 78.9% of revenue.

Commissions and incentives expense for fiscal 2026 was $77.1 million, or 42.2% of revenue, compared to $102.3 million, or 44.7% of revenue in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year is primarily due to changes in the sales mix between our independent consultants and customers along with the timing and magnitude of promotional and incentive programs.

Selling, general and administrative (SG&A) expense for fiscal 2026 was $58.4 million, or 32.0% of revenue, compared to $69.2 million, or 30.3% of revenue in fiscal 2025. The increase in SG&A expenses as a percentage of revenue was primarily due to an overall decrease in sales during the year partially offset by decreases in the variable portion of employee related compensation expenses.

Operating income for fiscal 2026 was $6.1 million compared to $12.2 million in fiscal 2025. Adjusted non-GAAP operating income for fiscal 2026 was $8.6 million compared to adjusted non-GAAP operating income of $13.3 million in fiscal 2025.

Net income for fiscal 2026 was $5.1 million, or $0.40 per diluted share, compared to $9.8 million, or $0.75 per diluted share in fiscal 2025. Adjusted non-GAAP net income for fiscal 2026 was $7.2 million, or $0.56 per diluted share, compared to adjusted non-GAAP income of $10.6 million, or $0.82 per diluted share in fiscal 2025.

Adjusted EBITDA was $13.7 million in fiscal 2026 versus $22.1 million in fiscal 2025.

Balance Sheet & Liquidity

The Company generated $10.2 million of cash from operations during fiscal 2026 compared to $11.9 million in fiscal 2025. The Company’s cash and cash equivalents at June 30, 2026 were $14.9 million, compared to $20.2 million at June 30, 2025, and there was no debt outstanding.

Share Repurchase

During fiscal 2026, the Company repurchased approximately 336,000 of its common shares for an aggregate price of approximately $2.0 million. As of June 30th, there was $58.5 million remaining under the $60 million share repurchase program approved by the Company’s Board of Directors in January.

Fiscal 2027 Guidance

Due to the recent transition in the Chief Executive Officer role, the Company is not issuing formal guidance for fiscal 2027 at this time.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim^® family of products, TrueScience^® Liquid Collagen, the MindBody GLP-1 System^®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience^® line of skin and hair care products, and Petandim^®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.